Product Description
For alzheimer disease
Mechanisms of Action: 5-HT1A Antagonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00499200 |
3197A1-1104 | P1 |
Completed |
Alzheimer Disease |
2008-06-01 |
2019-03-21 |
Treatments |
|
NCT00452504 |
3197A1-100 | P1 |
Completed |
Alzheimer Disease |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|